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Abstract: Sildenaﬁ  l was the ﬁ  rst orally administered phosphodiesterase-5 inhibitor approved 
for the treatment of erectile dysfunction. Its successful introduction into clinical practice was 
soon followed by the launch of two other phosphodiesterase-5 inhibitors: vardenaﬁ  l and tadala-
ﬁ  l. The plethora of choices made the question “which PDE-5 inhibitor?” relevant for patients 
and clinicians. Despite the lack of head-to-head comparative trials it is widely accepted that 
there are no signiﬁ  cant differences in their safety and efﬁ  cacy. Therefore a number of studies 
set out to determine which of the inhibitors patients would prefer and reasons for that prefer-
ence. The majority of published trials show a preference for tadalaﬁ  l. Others have argued that 
preference trials have several methodological ﬂ  aws and data favoring tadalaﬁ  l with its long 
duration of action do not reﬂ  ect real-life prescription ﬁ  lling and sales ﬁ  gures. But even if one 
of the available PDE-5 inhibitors is chosen to treat erectile dysfunction what is the long-term 
compliance? A signiﬁ  cant percentage of men initiating treatment switch between inhibitors or 
discontinue therapy. Reasons for that seem to often be unrelated to efﬁ  cacy or tolerability and 
include emotional and social factors determining couples’ and individuals’ sexual and treat-
ment seeking behavior.
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Introduction
Erectile dysfunction (ED) is a highly prevalent condition (Feldman et al 1994) affect-
ing millions of men worldwide. Before oral phosphodiesterase-5 (PDE-5) inhibitors 
became available, intracavernosal injection of vasoactive drugs was one of the com-
monly prescribed medical treatments. Despite its proven efﬁ  cacy, even in difﬁ  cult to 
treat cases, many patients discontinued it for various reasons, including penile pain, 
unnaturalness of erection and fear of the needle, and loss of sex drive: in clinical 
trials, the patient drop-out rate has been as high as 47% (Hanash 1997). Similar to 
intracavernosal injection therapy, high drop-out rates have also been reported in clini-
cal trials with intraurethral alprostadil, the other commonly prescribed ED treatment, 
and the most frequent reason for that was pain, either during the application or during 
erection and intercourse (Pangkahila 2000). Oral medication was expected to improve 
compliance compared with the above, relatively invasive, treatments.
In 1998, sildenaﬁ  l became an US Food and Drug Administration-approved oral 
treatment for ED. In the years after that, two more PDE-5 inhibitors, vardenaﬁ  l and 
tadalaﬁ  l, were developed and also approved in 2003 for the same indication. Despite 
their common mechanism of action, the three PDE-5 inhibitors have molecular differ-
ences that are reﬂ  ected in their pharmacokinetic properties and selectivity for different 
PDE isozymes (Carson and Lue 2005). With the exception of tadalaﬁ  l’s long duration 
of action, the impact of the molecular differences in clinical outcomes is negligible Patient Preferences and Adherence 2008:2 150
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and all three drugs share good efﬁ  cacy and satisfactory 
safety/tolerability proﬁ  les (Doggrell 2007).
There are currently more treatment options available 
for erectile dysfunction than ever. Oral pharmacotherapy is 
noninvasive, reversible, and easy to administer. Therefore 
PDE-5 inhibitors are the ﬁ  rst option for treatment of ED 
for both patients and physicians (Hatzimouratidis and 
Hatzichristou 2005). It would be reasonable to assume that 
since oral PDE-5 inhibitors combine ease of administration, 
high efﬁ  cacy, and good tolerability, compliance to long-
term treatment would be high. Relevant reports, discussed 
in the adherence section of this review, indicate that despite 
initial enthusiasm a signiﬁ  cant number of patients abandon 
treatment. The availability of three, more or less similar, drugs 
makes choosing one somewhat difﬁ  cult and often patients 
switch from one to another. Given the lack of signiﬁ  cant 
differences in efficacy and safety, treatment preference 
becomes increasingly important as adherence to the preferred 
drug would be higher.
Results from studies on PDE-5 inhibitor preference and 
factors inﬂ  uencing it as well on adherence to treatment pub-
lished in peer-reviewed journals are reported in this paper 
and interpreted from a clinician’s point of view.
Preference studies
A number of preference studies have been conducted so far 
aiming to determine patient preference for one PDE-5 inhibitor 
over another. Most of these studies have compared sildenaﬁ  l 
and tadalaﬁ  l, but a few have also included vardenaﬁ  l.
In a multicenter, open label, ﬁ  xed-dose, one-way cross-
over trial (Ströberg et al 2003), 147 patients using sildenaﬁ  l 
20, 50, or 100 mg as needed for at least 6 weeks prior to the 
study were assessed and then switched to tadalaﬁ  l 20 mg 
as needed. Treatment-speciﬁ  c instructions were given with 
emphasis on the pharmacokinetic properties of the two PDE-5 
inhibitors. 90.5% of patients preferred to receive tadalaﬁ  l in 
a 6-month extension phase of this trial compared with 9.5% 
who preferred sildenaﬁ  l. This preference seemed to be the 
same irrespective of patient age group, ED etiology and 
severity, and sildenaﬁ  l dose at study entry.
At the same time another multicenter, randomized, 
double-blind, ﬁ  xed-dose, two 4-week period crossover trial 
of tadalaﬁ  l 20 mg or sildenaﬁ  l 50 mg investigated men’s 
preference for initiation of ED treatment (Govier et al 
2003). Of 190 evaluable patients, 126 (66.3%) preferred to 
initiate treatment with tadalaﬁ  l compared with 64 (33.7%) 
who preferred sildenaﬁ  l. Patient age group, duration of ED, 
sequence of administration, previous exposure to sildenaﬁ  l, 
and the presence of comorbidities (diabetes, cardiovascular 
disease) did not affect preference.
In 2004, a study assessing not only drug preference for 
tadalaﬁ  l or sildenaﬁ  l, but also dosing instruction preference 
was published (von Keitz et al 2004). In this randomized, 
double-blind, crossover trial, 219 patients were allocated 
to either sildenaﬁ  l 50 mg or tadalaﬁ  l 20 mg for drug prefer-
ence assessment. Respective dosing instructions were given. 
Another 46 men were randomized to tadalaﬁ  l 20 mg with 
either tadalaﬁ  l or sildenaﬁ  l instructions for assessment of 
dosing instruction preference while on tadalaﬁ  l therapy. 
66% of patients had used sildenaﬁ  l prior to the trial and 
nonresponders to sildenaﬁ  l were allowed in the study. A 
sham-placebo methodology was used to maintain the blind. 
Patients receiving sildenaﬁ  l were offered the opportunity of 
an upward dose titration, but only 35% actually received it 
to mimic the pattern of sildenaﬁ  l dose usage in the market. 
The remaining 65% received placebo dose titration, always 
in a double-blind fashion. In the drug preference assessment 
73% of evaluable patients chose to receive tadalaﬁ  l during an 
extension period compared with 27% who preferred sildena-
ﬁ  l. In the dosing instruction preference assessment, 67% of 
patients preferred tadalaﬁ  l dosing instructions.
In 2005, a multicenter, randomized, open-label, crossover 
trial of two 12-week treatment periods compared preference 
between tadalaﬁ  l and sildenaﬁ  l (Eardley et al 2005). 367 
men with ED naïve to PDE-5 inhibitors received the rec-
ommended starting dose for both drugs initially and could 
titrate to their optimum dose before the assessment period. 
48.4% of patients titrated to the 20 mg tadalaﬁ  l dose while 
30.6% titrated to 100 mg sildenaﬁ  l. Of 291 men completing 
treatment with both drugs, 71% preferred tadalaﬁ  l and 29% 
preferred sildenaﬁ  l for the treatment of ED in an 8-week 
extension period. According to the authors, the small dif-
ferences observed in certain efﬁ  cacy parameters could not 
explain the difference in drug preference. In a later publica-
tion of data from this study (Dean et al 2006), tadalaﬁ  l was 
signiﬁ  cantly superior in improving patient psychosocial 
outcomes (Psychological and Interpersonal Relationship 
Scales [PAIRS] Domain scores) and this could probably 
account for the observed preference for tadalaﬁ  l. In a post 
hoc analysis, baseline patient characteristics were not sig-
niﬁ  cantly associated with, and could not predict preference 
(Eardley et al 2007).
In 2006, a study evaluating in everyday clinical practice 
drug preference for the long-acting PDE-5 inhibitor, tadalaﬁ  l, 
against the short-acting PDE-5 inhibitors sildenaﬁ  l and 
vardenaﬁ  l combined was published (Ströberg et al 2006). 186 Patient Preferences and Adherence 2008:2 151
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ED outpatients eligible for treatment with PDE-5 inhibitors 
were prescribed eight tablets of the short-acting PDE-5 
inhibitors at their maximum dose (4 tablets sildenaﬁ  l 100 
mg and 4 tablets vardenaﬁ  l 20 mg) and eight 20 mg tablets 
of the long-acting inhibitor tadalaﬁ  l. Respective instructions 
were given. Patients were advised to start with the short-
acting tablets and use all doses before starting the long-
acting ones without instructions for washout between drugs. 
Compliance to this regimen was not recorded. One third 
of the study population were naïve to treatment and the 
remainder already undergoing treatment with sildenaﬁ  l (76 
patients), vardenaﬁ  l (6 patients), tadalaﬁ  l (32 patients), or 
intraurethral/ intracavernosal medication (6 patients). 145 
patients completed the programme trying all three drugs 
and 138 were considered responders. 55% of these patients 
preferred to continue their treatment with tadalaﬁ  l, 27% with 
sildenaﬁ  l, and 17% with vardenaﬁ  l. Difference of preference 
between short- and long-acting was not signiﬁ  cant (55% vs. 
44%) in the entire study populationm, but naïve men seem 
to prefer the short-acting ones (60%) and nonnaive the long-
acting inhibitors (64%).
Another multicentre, noninterventional, observational 
study assessing preference for sildenafil or tadalafil in 
clinical practice was also published in 2006 (Lee et al 2006). 
2425 men changing treatment from sildenaﬁ  l to tadalaﬁ  l or 
vice versa participated in the study. Patients could choose 
between sildenaﬁ  l and tadalaﬁ  l, have no preference, prefer 
other treatment or prefer to stop treatment for ED. Of 1645 
men taking sildenaﬁ  l at baseline and changing to tadalaﬁ  l, 
70% preferred tadalaﬁ  l, and 17% sildenaﬁ  l. Of 679 men 
taking tadalaﬁ  l at baseline and changing to sildenaﬁ  l, 59% 
preferred tadalaﬁ  l and 28% sildenaﬁ  l. Data from this study 
published separately (Brock et al 2007) showed higher treat-
ment satisfaction with tadalaﬁ  l: authors stated that this might 
help explain greater preference for tadalaﬁ  l. This was the ﬁ  rst 
study to also assess physician ratings of patient preference 
as well as partner preference. Responses to the preference 
questionnaires showed that physician-rated patient prefer-
ence, patient preference, and partner preference had a similar 
pattern all favoring tadalaﬁ  l. Men who preferred tadalaﬁ  l 
did so because of its longer duration of action and quality 
of achieved erections.
In the same year a prospective, randomized, open-label, 
ﬁ  xed-dose, 3-period crossover study also included all three 
available PDE-5 inhibitors (Tolrà et al 2006). The same 
number of naive to treatment men, with moderate to mild ED, 
were randomized in one of 6 drug sequence groups for silde-
naﬁ  l 100 mg, vardenaﬁ  l 20 mg, and tadalaﬁ  l 20 mg, and had 
at least 6 tablets of each with 1 week washout period between 
them. Of 90 men who completed the protocol 27.77% chose 
sildenaﬁ  l, 20% vardenaﬁ  l, and 52.22% tadalaﬁ  l in the drug 
preference assessment.
Preference for sildenaﬁ  l or vardenaﬁ  l has been assessed 
in men with ED and risk factors for cardiovascular disease 
(Rubio-Aurioles et al 2006). Data from two multicenter, 
randomized, double-blind, 2 – period crossover studies were 
pooled. 1057 patients with ED and a medical history/diagno-
sis of diabetes mellitus, hypertension, and/ or hyperlipidemia 
were randomized to receive sildenaﬁ  l 100 mg or vardenaﬁ  l 
20 mg for 4 weeks. This was followed by a 1-week washout 
before switching to the other treatment. 931 men, 67% of 
whom had previously used sildenaﬁ  l, were included in the 
Intent-To-Treat analysis. The overall preference was 38.9% 
for vardenaﬁ  l and 34.5% for sildenaﬁ  l. 26.6% of patients 
had no preference.
Adherence to PDE-5 inhibitor 
treatment
In an update on the safety of sildenaﬁ  l published four years 
after its launch (Padma-Nathan et al 2002), 32% of patients 
in open-label extension of double-blind, placebo controlled 
clinical trials had discontinued study treatment by the end 
of the 3-year follow up. Nearly half of discontinuations 
occurred during the ﬁ  rst year but most of them (79%) were 
not treatment related.
To investigate adherence to treatment in real-life, where 
patients initiate it outside the context of clinical trials, several 
studies have been conducted. Soon after the introduction of 
sildenaﬁ  l into clinical practice the Dutch cohort of sildenaﬁ  l 
users was formed to gather information on medication 
utilization patterns through pharmacy prescription recording 
(Souverein et al 2002). 317 men ﬁ  lling their ﬁ  rst sildenaﬁ  l 
prescription were followed up for a mean duration of 
18 months: 153 had previously used ED prescription drugs 
and 164 had not. 48% of previous ED medication users and 
45% of ﬁ  rst time users discontinued sildenaﬁ  l treatment 
during the follow-up period. Patients with a history of drug 
treatment for ED were nearly eight times as likely to switch 
to or re-start another ED prescription drug after discontinuing 
sildenaﬁ  l compared to previously untreated users who tended 
to stop treatment for ED altogether. Age over 60 years, 
urinary incontinence, and use of insulin or antidepressants 
were associated with an increased likelihood of sildenaﬁ  l 
discontinuation.
A retrospective evaluation of efﬁ  cacy, safety, and drug 
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between 1999 and 2001 was conducted through hospital 
database chart review, mailed questionnaires and telephone 
interviews (Jiann et al 2003). The prescription reﬁ  ll rate was 
66% in responders and 26% in non-responders. In a more 
recent publication of data from the same institution (Jiann 
et al 2006), 57% of 444 successfully treated men (responded 
“yes” to the question “Did you have satisfactory sexual inter-
course with Viagra® treatment?”) had stopped using sildenaﬁ  l 
at a mean follow-up of 3 years. The most common reason 
for that was effectiveness below expectations. Other reasons 
included high cost, loss of interest in sex, and inconvenience 
in obtaining the medication. Interestingly, adverse events 
were low on the list of reasons for discontinuation and the 
incidence of such events was higher in patients continuing 
treatment than in ones stopping it.
Discontinuation rate at 6 months and reasons for it were 
assessed by chart review or telephone interview in a cohort 
of 156 men whose erectile function was restored (Interna-
tional Index of Erectile Function [IIEF] score 26) with 
sildenaﬁ  l treatment (Son et al 2004). 35% discontinued 
sildenaﬁ  l medication. The reasons for it were primarily 
emotional or relationship-oriented and included shortcom-
ings in the partners’ or patients’ emotional readiness for the 
restoration of sexual life after long-term abstinence (37%), 
fear of possible side effects (18%), recovery of spontaneous 
erection (15%), postponement of ED treatment because of 
comorbid disease treatment (11%), unwillingness to accept 
drug-dependent erection (7%), high drug cost (4%), unac-
ceptability of planned sexual activity (4%), and lack of sexual 
interest (4%).
In a prospective study of 234 patients with mild to moder-
ate ED who had successfully begun treatment with sildenaﬁ  l 
50 or 100 mg in routine clinical practice (Klotz et al 2004), 
31% did not get a second prescription within 6 months of 
the ﬁ  rst. Reasons for discontinuing effective sildenaﬁ  l treat-
ment in this study included lack of opportunities or desire for 
intercourse for 45% of patients, and partner’s loss of sexual 
interest for 23% of cases. High treatment cost and side effects 
were reported as causes of abandoning treatment in 12% and 
5%, respectively.
The NDC Health’s Intelligent Health Repository (IHR), 
a databank of more than 40,000 US pharmacies, was used to 
identify men initiating ED treatment with one of the available 
PDE-5 inhibitors between November 2003 and March 2004 
(Mulhall et al 2005). The frequency of medication reﬁ  lls, 
dose titration, and switching were analyzed for 146,000 
men. While reﬁ  ll rates were signiﬁ  cantly higher for sildenaﬁ  l 
compared with vardenaﬁ  l or tadalaﬁ  l, they were low for all 
three inhibitors. Only 52%, 30%, and 29% reﬁ  lled their 
prescription for sildenaﬁ  l, vardenaﬁ  l, and tadalaﬁ  l within 
6 months of initial prescription, respectively.
In a recently published study in 1036 Japanese men 
(Sato et al 2007), 31% failed to reﬁ  ll their ﬁ  st prescription of 
sildenaﬁ  l. Almost 50% of the patients dropped out at 3 years 
despite successful initial treatment. A lower IIEF abbreviated 
version (IIEF-5) score before treatment was a signiﬁ  cant risk 
factor for dropout.
Higher treatment continuation rates were reported in a 
large prospective observational, noninterventional trial in 
Europe. 8047 men with ED who began (5116) or changed 
ED therapy as part of their routine healthcare were followed 
up for a period of 6 months (Hatzichristou et al 2007). In an 
analysis of data from treatment-naïve patients with 6 month 
follow-up data (4026), most continued on the same PDE-5 
inhibitor throughout the study regardless of what PDE-5 
inhibitor they were prescribed at baseline. Continuation 
rates were approximately 89% in the tadalaﬁ  l cohort and 
63%–64% in the sildenaﬁ  l and vardenaﬁ  l cohorts. Authors 
suggested that ﬁ  ndings of the study should be interpreted 
conservatively due to its observational nature.
Conclusion
Most preference trials favor tadalaﬁ  l among available PDE-5 
inhibitors but have methodological ﬂ  aws that allow bias 
introduction and limit extrapolation or results in clinical 
practice. Long-term adherence to PDE-5 inhibitors seems 
to be low despite their high efﬁ  cacy, good tolerability, and 
ease of administration. A better understanding of factors 
that inﬂ  uence sexual behavior and thus drug utilization is 
mandatory in achieving patient satisfaction and compliance 
to treatment.
Discussion
The introduction of orally administered PDE-5 inhibitors has 
revolutionized the management of erectile dysfunction. The 
availability of several treatment alternatives should, ideally, 
allow patients to ﬁ  nd the one that suits their own needs and 
expectations. In reality the abundance of alternatives poses 
the dilemma of drug choice. The lack of clinically meaning-
ful differences in safety and efﬁ  cacy of available PDE-5 
inhibitors, the ﬁ  rst-line ED treatment, makes this decision 
even harder.
Many studies have attempted to deﬁ  ne patient prefer-
ence and help them, as well as physicians, in their choice of 
treatment. Most have been presented as abstracts in various 
congresses and frequently study methods are inadequately Patient Preferences and Adherence 2008:2 153
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described. Only 8 have been published as full papers in 
peer-reviewed journals and are summarized in this review. 
Five of the available eight studies have assessed preference 
between sildenaﬁ  l and tadalaﬁ  l, all favoring tadalaﬁ  l (chosen 
by 59% to 90% of patients). One combined sildenaﬁ  l and 
vardenaﬁ  l as short-acting PDE-5 inhibitors and compared 
them with the long-acting tadalaﬁ  l, again favoring tadalaﬁ  l. 
Vardenaﬁ  l was compared with sildenaﬁ  l in one trial aiming 
to prove noninferiority of vardenaﬁ  l, only slightly favoring 
vardenaﬁ  l. Just one of the published studies included all three 
PDE-5 inhibitors individually and tadalaﬁ  l was once more 
the preferred treatment.
Data on preference is not conclusive and comparing pub-
lished trials is difﬁ  cult due to different patient populations 
and study designs. In a 2004 paper, methodological ﬂ  aws 
of initial studies have been discussed and recommendations 
for minimizing bias have been proposed (Mulhall 2004). 
Double-blinding of drug administration, randomization of 
drug administration sequence, nonbiased drug administration 
instructions, adequately conducted crossover, comparison of 
equivalent drug doses for treatment periods of equal length, 
standardized preference assessment, declaration of patient 
demographics, and rigorous statistical analysis are consid-
ered important characteristics of an adequately designed and 
conducted preference trial. Unfortunately available studies 
have failed to demonstrate these characteristics (Mulhall 
and Montorsi 2006) thus hindering interpretation of data and 
extrapolation of results to clinical practice.
Reasons for preference of one drug over another have 
been assessed in some of the existing studies. In the major-
ity of those, patient age group, ED etiology and severity, 
and in general baseline demographic characteristics were 
not associated with, and thus couldn’t predict, preference 
(Ströberg et al 2003; Govier et al 2003; Eardley et al 2007). 
One study suggested that naïve to PDE-5 inhibitors patients 
may prefer short-acting inhibitors while nonnaïve may prefer 
the long-acting tadalaﬁ  l (Ströberg et al 2006). Superiority of 
tadalaﬁ  l in patient satisfaction and improvement in psychoso-
cial outcomes has been suggested as a reason for preference 
for tadalaﬁ  l (Dean et al 2006; Lee et al 2006). Other factors 
that may inﬂ  uence preference such as lifestyle issues and 
partner preference are not well understood. In fact partner 
of ED-patient preference has been assessed only in one of 
available studies (Lee et al 2006). Despite the preference for 
tadalaﬁ  l (76% in the group changing treatment from sildenaﬁ  l 
to tadalaﬁ  l and 65% in the group changing from tadalaﬁ  l 
to sildenaﬁ  l) the inﬂ  uence of partner to patient preference 
and vice versa in not known. A considerable proportion of 
patients seem to have preferred tadalaﬁ  l in trials because of 
its long duration of action. This can allow dissociation of 
drug administration from intercourse attempt making sex 
more spontaneous. Whether men are actually using this drug 
property in every-day life is a subject of debate. In an analy-
sis of data combined from two randomized controlled trials 
assessing the frequency, timing and success of intercourse 
attempts in men with erectile dysfunction using tadalaﬁ  l 
(Hatzichristou et al 2005), 63% of them made at least a 
quarter of their attempts and 42% made at least half of their 
attempts more than 4 hours after dose. Still, a signiﬁ  cant 
number of attempts were made within 4 hours of taking the 
pill indicating that some connection of dosing to intercourse 
attempt is important even for tadalaﬁ  l.
Have preference trials really helped in clinical decision 
making? Even though most studies show a preference for 
tadalaﬁ  l, they have, as mentioned before, methodological 
ﬂ  aws that allow for bias introduction. Furthermore the major-
ity of these trials have been conducted right after launch of 
new PDE-5 inhibitors possibly allowing the effect of media 
publicity and novelty of product on preference. They have 
used single preference questions generating responses that 
are subject to contextual limitations. Another issue raised is 
that preference for tadalaﬁ  l in trials has not been conﬁ  rmed 
in routine clinical practice data. Prescription renewal has 
been used as a method of indirectly assessing patient prefer-
ence and adherence as it reﬂ  ects many aspects of treatment: 
efﬁ  cacy, safety, cost considerations, and overall satisfaction 
from treatment experience. In a retrospective cohort study 
using prescription data of 2703 men initiating therapy for ED 
with one of the available PDE-5 inhibitors, patients who were 
originally prescribed sildenaﬁ  l were nearly 4 times less likely 
to switch to another inhibitor on their second prescription 
compared with patients who were prescribed either tadalaﬁ  l 
or vardenaﬁ  l (Kell et al 2007). In another study mentioned 
above (Mulhall et al 2005) reﬁ  ll rates were signiﬁ  cantly 
higher for sildenaﬁ  l compared with vardenaﬁ  l or tadalaﬁ  l. 
Of course other studies have contradicted these results 
(Hatzichristou et al 2007). Prescription renewal studies have 
limitations including but not limited to inability to account 
for prescriptions that were ﬁ  lled but medication never used 
or getting the drug from alternative sources like the internet. 
In conclusion there is no evidence-based guidance for either 
clinicians or patients regarding PDE-5 inhibitor choice. This 
can only be made after careful patient assessment and educa-
tion. Patient expectations, and broader than efﬁ  cacy lifestyle 
factors, are important in identifying the right treatment for 
the right patient.Patient Preferences and Adherence 2008:2 154
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After the choice of a certain treatment has been made 
the question “do patients adhere to that treatment?” comes 
naturally. Most of the available adherence data concern 
sildenaﬁ  l and were obtained in a period of time when this 
was the only PDE-5 inhibitor on the market. After vardenaﬁ  l 
and tadalaﬁ  l became available interest shifted to assessing 
switching between the 3 inhibitors and less is known for the 
adherence to the class in general. The majority of published 
data indicates that between 30% and 60% of initially success-
fully treated and satisﬁ  ed men stop reﬁ  lling their medication 
prescriptions. Diversity in study populations, duration of 
follow-up and methods of assessment, might account for the 
different results of various studies. A signiﬁ  cant proportion 
of discontinuations occur within one year of treatment initia-
tion and many men do not even ﬁ  ll a second prescription. 
Discontinuation rates are, of course, higher and abandon-
ment of treatment occurs earlier in patients with suboptimal 
treatment response.
Factors that have been associated with a higher prob-
ability of discontinuing treatment include age over 60 years, 
the presence of comorbidities as evidenced by the use of 
incontinence products, insulin, or antidepressants (Souverein 
et al 2002) and severe ED (lower IIEF-5 scores) ( Sato et al 
2007). In these patients inadequate treatment response could 
be responsible for the higher discontinuation rates. As efﬁ  -
cacy is very important for repeating a prescription techniques 
that optimize it such as adequate administration instructions 
and dose titration (McCullough et al 2006; Steidle et al 2007) 
may improve adherence. Nevertheless it is clear that efﬁ  cacy 
is only one of the factors inﬂ  uencing adherence to treatment: 
discontinuation rates are high even if ED is successfully 
managed. Emotional and relationship factors play a very 
important role in this. Reasons for abandoning successful 
treatment are unmet efﬁ  cacy expectations, loss of interest 
in sex, lack of opportunities or desire for intercourse, and 
partner reluctance or unwillingness. Financial reasons have 
also been sited as reason for discontinuation but not as often 
as emotional or relationship factors. Given the efﬁ  cacy and 
safety of all available PDE-5 inhibitors, it seems that patient 
education and understanding of their beliefs, practices, needs 
and expectations is the only way to ﬁ  nd the right treatment 
and improve adherence to long-term use.
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